Provided by Tiger Trade Technology Pte. Ltd.

Syntara Ltd

0.032
-0.001-3.03%
Volume:717.85K
Turnover:23.26K
Market Cap:52.24M
PE:-5.94
High:0.033
Open:0.033
Low:0.031
Close:0.033
52wk High:0.095
52wk Low:0.023
Shares:1.63B
Float Shares:1.00B
Volume Ratio:0.28
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.005
EPS(LYR):-0.005
ROE:-118.44%
ROA:-49.40%
PB:3.26
PE(LYR):-5.94

Loading ...

Company Profile

Company Name:
Syntara Ltd
Exchange:
ASX
Establishment Date:
1998
Employees:
- -
Office Location:
20A Rodborough Road,Unit 2,Frenchs Forest,New South Wales,Australia
Zip Code:
2086
Fax:
61 2 9451 3622
Introduction:
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, pulmonary fibrosis, liver, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO/MPO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.